Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica.
Avonex approval application
Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation.
Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis.
Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report.
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.
Randomized study combining interferon & glatiramer acetate in multiple sclerosis.
Understanding the Metabolic Consequences of Human Arylsulfatase A Deficiency through a Computational Systems Biology Study.
Interferon beta-1b
Neuroimmunology: Phase II trial demonstrates efficacy of erythropoietin in optic neuritis.
Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
Oligodendrocytes and progenitors become progressively depleted within chronically demyelinated lesions.
Effirma, Synthetic Biologics
Rituximab does not reset defective early B cell tolerance checkpoints.
European Commission approves Genzyme’s multiple sclerosis treatment Lemtrada™ (alemtuzumab)
[Flow cytometry model for the detection of neutralizing antibodies against of IFN-β].
The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform.
Regulation of brain endothelial barrier function by microRNAs in health and neuroinflammation.
The force awakens: insights into the origin and formation of microglia.
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.
Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.
Dimethylfumarate Impairs Neutrophil Functions.
Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.
Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

Pages